Evaluation of STX-478 Monotherapy and Combination Therapy in Patients with Advanced Solid Tumors, Including Breast Cancer and Head and Neck Squamous Cell Carcinoma

The primary objective of this study is to evaluate the efficacy and safety of **STX-478** as a monotherapy and in combination with other anticancer agents in participants with advanced solid tumors, including but not limited to **breast cancer**, gynecologic cancer, and **head and neck squamous cell carcinoma**. This is clinically relevant as it aims to determine the potential of STX-478 to improve treatment outcomes in these challenging cancer types, which often have limited therapeutic options and poor prognosis.

The clinical trial involves a total of **140 participants** diagnosed with **Breast Cancer**, advanced solid tumors including but not limited to gynecologic cancer, and **Head and Neck Squamous Cell Carcinoma**. The study population comprises both male and female subjects, with an age range that includes adults and older adults. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify particular lifestyle considerations such as diet or physical activity. The sponsor has not provided detailed information on the main objective or principal inclusion criteria for the study.

The clinical trial is designed to evaluate the efficacy and safety of **STX-478** alone and in combination with other anticancer drugs in participants with advanced solid tumors, including but not limited to **breast cancer**, gynecologic cancer, and head and neck squamous cell carcinoma. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the investigators know which treatment the participants are receiving, thereby minimizing bias. The estimated duration of the trial is from September 2024 to June 2026, with participant involvement expected to last throughout this period unless early termination criteria are met.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This visit will involve a comprehensive evaluation of the participant's medical history, current health status, and specific diagnostic tests to confirm the presence of the targeted medical conditions. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits. These visits are scheduled to monitor the participant's response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. The end-of-study visit will conclude the participant's involvement, during which final assessments will be conducted to evaluate the overall outcomes of the treatment.

Participant involvement is expected to last until the trial's completion, unless specific conditions necessitate early withdrawal. Such conditions may include significant adverse reactions to the treatment, non-compliance with the study protocol, or withdrawal of consent by the participant. The trial's design and procedures are meticulously planned to ensure the collection of reliable data while prioritizing participant safety and well-being.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available. Consequently, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not included. The absence of these details precludes a comprehensive description of the treatments used in this clinical trial.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is set to commence recruitment on September 4, 2024, with an estimated completion date of June 1, 2026. The trial is categorized under phase 7, indicating a specific stage in the clinical research process. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's effectiveness. The methodology for assessing efficacy will adhere to standard clinical trial protocols, ensuring that results are scientifically valid and reliable. The trial will employ appropriate tools and instruments to measure outcomes, although these are not specified in the available data. The efficacy assessment will be conducted at predetermined intervals throughout the trial duration, ensuring comprehensive evaluation of the treatment's impact over time.